Michael Barbella, Managing Editor02.06.23
Japan's diabetes care devices market is headed for a sweet future.
The country is a significant contributor to the Asia-Pacific (APAC) diabetes care devices sector, capturing almost 25% share in the region in 2022. Globaldata projects the sector to expand approximately 4% annually through 2030, driven by growth in type 2 diabetes among the aging population and lifestyle changes.
Insulin pens continue to be at the heart of medical device innovation in diabetes management due to advances in technology, ease of usage, patient satisfaction, and cost-effectiveness.
“Novo Nordisk AS is currently the leading player in the diabetes device market, followed by Eli Lilly and Sanofi," said Ayshi Ganguly, a medical devices analyst at GlobalData. "Novo Nordisk AS has established its market position by continuously investing in the research and development and by working with other organizations to introduce advanced technologies into their insulin pens that make insulin administration as easy and convenient as possible.”
Biocorp and Novo Nordisk have stepped up their collaboration to commercialize Mallya smart sensors to the Japanese market in the first quarter of 2023. Mallya, which connects directly to Novo Nordisk's existing insulin pens, will automatically collect, and record daily insulin injection data via a mobile application to track real-time therapy monitoring. Novo Nordisk claims to have launched Japan's first smart insulin pen last year.
“Japan is one of the high-potential markets for the development of diabetes care devices," Ganguly said. "Further collaborations and innovations will enable domestic and foreign companies to expand their networks and increase market share in the country.”
The country is a significant contributor to the Asia-Pacific (APAC) diabetes care devices sector, capturing almost 25% share in the region in 2022. Globaldata projects the sector to expand approximately 4% annually through 2030, driven by growth in type 2 diabetes among the aging population and lifestyle changes.
Insulin pens continue to be at the heart of medical device innovation in diabetes management due to advances in technology, ease of usage, patient satisfaction, and cost-effectiveness.
“Novo Nordisk AS is currently the leading player in the diabetes device market, followed by Eli Lilly and Sanofi," said Ayshi Ganguly, a medical devices analyst at GlobalData. "Novo Nordisk AS has established its market position by continuously investing in the research and development and by working with other organizations to introduce advanced technologies into their insulin pens that make insulin administration as easy and convenient as possible.”
Biocorp and Novo Nordisk have stepped up their collaboration to commercialize Mallya smart sensors to the Japanese market in the first quarter of 2023. Mallya, which connects directly to Novo Nordisk's existing insulin pens, will automatically collect, and record daily insulin injection data via a mobile application to track real-time therapy monitoring. Novo Nordisk claims to have launched Japan's first smart insulin pen last year.
“Japan is one of the high-potential markets for the development of diabetes care devices," Ganguly said. "Further collaborations and innovations will enable domestic and foreign companies to expand their networks and increase market share in the country.”